I sure don’t know everything, but why mention it then? It’s just normal? Or is this new for the US?
How is it negotiation when there is only one medicine, like in the case of insulin, or even Zolgensma? What chips does the government have to negotiate with? Buying power doesn’t matter.
I still think that’s screwed up, and needs fixing, but if it brought us in line with the rest of the world when it comes to drug prices, then bring it on.
They are negotiating the prices paid for drugs by Medicare. You know, like, the largest single purchaser of drugs in the country. That purchase power was not being negotiated prior. They have started with a list of 10 drugs and will expand over time. This can affect prices in a few ways, like insurers saying fuck that and wanting the same rate as the government, manufacturers could set the pricing to match across the board like Eli Lilly did for insulin for non Medicare patients, or we could vote for a fully democratic Senate, house, and president and get Medicare for all, with which this existing law would wield immense powers to negotiate far more benefits for many more people. Gimme 63 Dems in the Senate and shit will get passed. The reason we are stuck like this is that the margin is so slim nothing can happen.
Here’s a quote from the HHS.
The selected drug list for the first round of negotiation is:
Eliquis
Jardiance
Xarelto
Januvia
Farxiga
Entresto
Enbrel
Imbruvica
Stelara
Fiasp; Fiasp FlexTouch; Fiasp PenFill; NovoLog; NovoLog FlexPen; NovoLog PenFill
These selected drugs accounted for $50.5 billion in total Part D gross covered prescription drug costs, or about 20%, of total Part D gross covered prescription drug costs between June 1, 2022 and May 31, 2023, which is the time period used to determine which drugs were eligible for negotiation. CMS will publish any agreed-upon negotiated prices for the selected drugs by September 1, 2024; those prices will come into effect starting January 1, 2026. In future years, CMS will select for negotiation up to 15 more drugs covered under Part D for 2027, up to 15 more drugs for 2028 (including drugs covered under Part B and Part D), and up to 20 more drugs for each year after that, as outlined in the Inflation Reduction Act.
I sure don’t know everything, but why mention it then? It’s just normal? Or is this new for the US?
How is it negotiation when there is only one medicine, like in the case of insulin, or even Zolgensma? What chips does the government have to negotiate with? Buying power doesn’t matter.
I still think that’s screwed up, and needs fixing, but if it brought us in line with the rest of the world when it comes to drug prices, then bring it on.
They are negotiating the prices paid for drugs by Medicare. You know, like, the largest single purchaser of drugs in the country. That purchase power was not being negotiated prior. They have started with a list of 10 drugs and will expand over time. This can affect prices in a few ways, like insurers saying fuck that and wanting the same rate as the government, manufacturers could set the pricing to match across the board like Eli Lilly did for insulin for non Medicare patients, or we could vote for a fully democratic Senate, house, and president and get Medicare for all, with which this existing law would wield immense powers to negotiate far more benefits for many more people. Gimme 63 Dems in the Senate and shit will get passed. The reason we are stuck like this is that the margin is so slim nothing can happen.
Here’s a quote from the HHS.
There are 3 companies that produce insulin. Why don’t you ask some of your Canadian neighbors how much they pay for insulin.